Bronchiectasis in secondary care: A comprehensive profile of a neglected disease

European Journal of Internal Medicine

Volumn 14, Issue 8, 2003, Pages 488-492

  Kelly, Martin G ^a   Murphy, S ^a   Elborn, J Stuart ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Audit; Bronchiectasis; Outpatients

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; PREDNISOLONE; STEROID; THEOPHYLLINE DERIVATIVE;

ADULT; ARTICLE; BACTERIUM ISOLATE; BRONCHIECTASIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBROSIS; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASLES; NEBULIZER; PATHOGENESIS; PERTUSSIS; PNEUMONIA; PSEUDOMONAS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 1142297588     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2003.10.002     Document Type: Article

References (27)

1. Girod C.E., Schwarz M.I. Other large-airway diseases that limit airflow limitation. Voekel N.F., MacNee W. Chronic obstructive lung diseases. 2002;190 BC Decker, Hamilton.
2. Marwah O.S., Sharma O.P. Bronchiectasis: how to identify, treat and prevent. Postgrad. Med. 97:(2):1995;153-156.
3. Hansell D.M. Bronchiectasis. Radiol. Clin. North Am. 36:(1):1998;107-128.
4. Gaga M., Bentley A.M., Humbert M., et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax. 53:1998;685-691.
5. Tsang H.W.T., Ho P.-K., Lam W.-K., et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am. J. Respir. Crit. Care Med. 158:1998;723-727.
6. Hovarth I., Loukides S., Wodehouse T., et al. Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax. 53:1998;867-870.
7. Keistinen T., Saynajakangas O., Tuuponen T., et al. Bronchiectasis: an orphan disease with a poorly understood prognosis. Eur. Respir. J. 10:1997;2784-2787.
8. Saynajakangas O., Keistinen T., Tuuponen T., et al. Bronchiectasis in Finland: trends in hospital treatment. Respir. Med. 91:1997;395-398.
9. Scala R., Aronne D., Palumbo U., et al. Prevalence, age distribution and aetiology of bronchiectasis: a retrospective study on 144 symptomatic patients. Monaldi Arch. Chest Dis. 55:(2):2000;101-104.
10. O'Brien C., Guest P.J., Hill S.L., et al. Physiological and radiological characteristics of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 55:(8):2000;635-642.
11. Pasteur M.C., Helliwell S.M., Houghton S.J., et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 162:2000;1277-1284.
12. Ambrosino N., Callegari G., Galloni C., et al. Clinical evaluation of oscillating positive expiratory pressure for expectoration in diseases other than cystic fibrosis. Monaldi Arch. Chest Dis. 50:(4):1995;269-275.
13. Jones A.P., Rowe B.H. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis. Cochrane Database Syst. Rev. 2:2000;CD000045.
14. Kolbe J., Wells A., Ram F.S. Inhaled steroids for bronchiectasis. Cochrane Database Syst. Rev. 2:2000;CD000996.
15. Elborn J.S., Johnston B., Allen F., et al. Inhaled steroids in patients with bronchiectasis. Respir. Med. 86:(2):1992;121-124.
16. Conway S.P., Watson A. Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis. Thorax. 52:(Suppl. 2):1997;S64-S68.
17. Dezateux C., Walters S., Balfour-Lynn I. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst. Rev. 1:2000;CD001915.
18. Burge P.S., Calverly P.M., Jones P.W., et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 320:2000;1297-1303.
19. Steele K., Greenstone M., Lasserson J.A. Oral methyl-xanthines for bronchiectasis. Cochrane Database Syst. Rev. 1:2001;CD002734.
20. Labiris N.R.C., Holbrook A.M., Chrystyn H., et al. Dry powder versus intravenous and nebulised gentamicin in cystic fibrosis and bronchiectasis. Am. J. Respir. Crit. Care Med. 160:1999;1711-1716.
21. Conway A. Home intravenous therapy for bronchiectasis patients. Nurs. Times. 92:(45):1996;34-35.
22. Winter R.J., George R.J., Deacock S.J., et al. Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis. Lancet. 1:(8390):1984;1338-1339.
23. Evans S.A., Turner S.M., Bosch B.J., et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur. Respir. J. 9:1996;1601-1604.
24. Wilson C.B., Jones P.W., O'Leary C.J., et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 10:1997;1754-1760.
25. Sheikh A., Nolan D., Greenstone M. Long-acting beta-2-agonists for bronchiectasis (Cochrane Review). Cochrane Database Syst. Rev. 4:2001;CD002155.
26. Corless J.A., Warburton C.J. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis. Cochrane Database Syst. Rev. 4:2000;CD002174.
27. Edmunds J., Pasteur M., Taylor G., et al. Investigation and management of bronchiectasis at a specialist clinic improves pulmonary function. Am. J. Respir. Crit. Care Med. (Suppl.):1999;D92. (poster 209).